Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves Four H1N1 Vaccines: HHS Touts Fast Response and Improved Infrastructure

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS Secretary Sebelius says H1N1 vaccine program has developed at "unprecedented speed"; government support for vaccine industry during past six years makes fast response possible.
Advertisement

Related Content

Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With Australia's CSL
Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With CSL
Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With CSL
J&J Buys $440 Mil. Stake In Crucell; Will Collaborate On Universal Flu Vaccine
J&J Buys $440 Mil. Stake In Crucell; Will Collaborate On Universal Flu Vaccine
Cervarix Passes Safety Hurdles; FDA Ponders Breadth of Protection Claim
Cervarix Passes Safety Hurdles; FDA Ponders Breadth of Protection Claim

Topics

Advertisement
UsernamePublicRestriction

Register

PS069971

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel